No formal clinical assessments of drug-drug interactions between azacitidine and other agents have been conducted. An in vitro study of azacitidine incubation in human liver fractions indicated that azacitidine may be metabolized by the liver. An in vitro study with cultured human hepatocytes indicated that azacitidine at concentrations up to 100 μM (IV Cmax = 10.6 μM) does not cause any inhibition of CYP2B6 and CYP2C8. In vitro studies with human cultured hepatocytes indicate that azacitidine at concentrations of 1.0 μM to 100 μM does not induce CYP 1A2, 2C19, or 3A4/5.